Less endocrine therapy in HR+/HER2- breast cancer: A nationwide trend despite unchanged guidelines
European Journal of Cancer · 2026-03 · 237 · 116626
DOI: 10.1016/j.ejca.2026.116626 ↗Kurz gefasst
Leitlinie in der Zeitschrift European Journal of Cancer, 2026-03. Verfasst von E. Verreck und 8 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Verreck, E., Postma, E., Oostergo, T., Meijer, J., Eijkelboom, A., Siesling, S., Rizopoulos, D., Dalen, T. V., & Volders, J. (2026). Less endocrine therapy in HR+/HER2- breast cancer: A nationwide trend despite unchanged guidelines. European Journal of Cancer, 237, 116626. https://doi.org/10.1016/j.ejca.2026.116626
Vancouver
Verreck E, Postma E, Oostergo T, Meijer J, Eijkelboom A, Siesling S, et al. Less endocrine therapy in HR+/HER2- breast cancer: A nationwide trend despite unchanged guidelines. European Journal of Cancer. 2026;237:116626. doi:10.1016/j.ejca.2026.116626
BibTeX
@article{Verreck2026,
author = {Verreck, E. and Postma, E. and Oostergo, T. and Meijer, J. and Eijkelboom, A. and Siesling, S. and Rizopoulos, D. and Dalen, T. van and Volders, J.},
title = {Less endocrine therapy in HR+/HER2- breast cancer: A nationwide trend despite unchanged guidelines},
journal = {European Journal of Cancer},
year = {2026},
volume = {237},
pages = {116626},
doi = {10.1016/j.ejca.2026.116626}
}
EUVIMED